Every time a new ANCA vasculitis clinical trial is announced, I do the same little dance. I read the headline, feel a flicker of hope, and then scroll down to the eligibility criteria looking for one acronym: EGPA, which stands for “eosinophilic granulomatosis with polyangiitis.” Most of the time,…
Discussion
Free-floating CD95L, a protein involved in inflammation and immune responses, is found at significantly higher levels in the blood of people with ANCA-associated vasculitis (AAV) and may be a potential treatment target, according to a study in France. Through a detailed series of experiments, researchers figured out that CD95L…
Discussion
Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
